Literature DB >> 30559052

Lenalidomide as maintenance for every newly diagnosed patient with multiple myeloma.

María-Victoria Mateos1, Verónica González de la Calle2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30559052     DOI： 10.1016/S1470-2045(18)30764-2

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  3 in total

1.  The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models.

Authors:  Shih-Feng Cho; Liang Lin; Lijie Xing; Yuyin Li; Kenneth Wen; Tengteng Yu; Phillip A Hsieh; Nikhil Munshi; Joachim Wahl; Katja Matthes; Matthias Friedrich; Tara Arvedson; Kenneth C Anderson; Yu-Tzu Tai
Journal:  Blood Adv       Date:  2020-09-08

Review 2.  Approaches and Challenges in the Management of Multiple Myeloma in the Very Old: Future Treatment Prospects.

Authors:  Natasha Mupeta Kaweme; Geoffrey Joseph Changwe; Fuling Zhou
Journal:  Front Med (Lausanne)       Date:  2021-02-25

Review 3.  Minimal residual disease detection by next-generation sequencing in multiple myeloma: Promise and challenges for response-adapted therapy.

Authors:  Valeria Ferla; Elena Antonini; Tommaso Perini; Francesca Farina; Serena Masottini; Simona Malato; Sarah Marktel; Maria Teresa Lupo Stanghellini; Cristina Tresoldi; Fabio Ciceri; Magda Marcatti
Journal:  Front Oncol       Date:  2022-08-16       Impact factor: 5.738
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.